POLA BAKTERI DAN USIA PASIEN TERHADAP PROKALSITONIN DI PNEUMONIA KOMUNITAS DAN NOSOKOMIAL

Pneumonia is one of an infectious disease with high mortality rate. In the last decade procalcitonin (PCT) was found as a biomarkerthat can predict a kind of infection. The aim of the study was to know the difference of PCT level between community acquired pneumonia(CAP) and hospital acquired pneumonia (HAP) by analyzing it, and the difference between <60 years old and older age patients. Across-sectional study was conducted on the CAP and HAP patients in RSHS, in August–October 2009. The level difference were analyzedwith Mann-Whitney test, with a significancy of p<0.05. In this study 40 (forty) patients (66%) CAP and 21 patients (34%) HAP wereincluded. The median of PCT levels in CAP was 0.88 ng/dL and HAP 8.32 ng/dL (p=0.002), where as in the in Gram negative bacterialinfection (GNBI) level in CAP was 4.76 ng/dL and in Gram positive was 0.61 ng/dL. The median PCT level in HAP with Gram negativewas 19.02 ng/dL and in the Gram positive was 4.63 ng/dL (p=0.201). The median of PCT level in CAP group <60 yo was 1.42 ng/dLand in ≥60 yo was 0.65 ng/dL (p=0.207). The median of PCT level in HAP <60 yo was 8.32 ng/dL, where as in ≥60 yo was 9.93ng/dL (p=0.178). Based in this study can be concluded that the PCT level in HAP group was higher than in the CAP group. The PCTlevel in HAP with Gram negative bacterial infection was higher than in the CAP, where as in the CAP group was lower in ≥60 yo.

Download Full-text

Microbiology of Ventilator–Associated Pneumonia Compared With That of Hospital-Acquired Pneumonia

Infection Control and Hospital Epidemiology ◽

10.1086/518460 ◽

2007 ◽

Vol 28 (7) ◽

pp. 825-831 ◽

Cited By ~ 92

Author(s):

David J. Weber ◽

William A. Rutala ◽

Emily E. Sickbert-Bennett ◽

Gregory P. Samsa ◽

Vickie Brown ◽

...

Keyword(s):

Staphylococcus Aureus ◽

Empirical Therapy ◽

Ventilator Associated Pneumonia ◽

Gram Positive ◽

Similar Frequency ◽

Gram Negative ◽

Hospital Acquired Pneumonia ◽

Hospital Acquired ◽

Gram Positive Cocci ◽

Ventilated Patients

Objective.Nosocomial pneumonia is the leading cause of mortality attributed to nosocomial infection. Appropriate empirical therapy has been associated with improved survival, but data are limited regarding the etiologic agents of hospital-acquired pneumonia in non-ventilated patients (HAP). This evaluation assessed whether the currently recommended empirical therapy is appropriate for both ventilator-associated pneumonia (VAP) and HAP by evaluating the infecting flora.Design.Prospectively collected hospitalwide surveillance data was obtained by infection control professionals using standard Centers for Disease Control and Prevention definitions.Setting.A tertiary care academic hospital.Patients.All patients admitted from 2000 through 2003.Results.A total of 588 episodes of pneumonia were reported in 556 patients: 327 episodes of VAP in 309 patients, and 261 episodes of HAP in 247 Patients. The infecting flora in ventilated patients included gram-positive cocci (32.0% [oxacillin-susceptible Staphylococcus aureus {OSSA}, 9.25%; oxacillin-resistant Staphylococcus aureus {ORSA}, 17.75%]), gram-negative bacilli (59.0% {Pseudomonas aeruginosa, 17.50%; Stenotrophomonas maltophilia, 6.75%; Acinetobacter species, 7.75%), and miscellaneous pathogens (9.0%). The infecting flora in nonventilated patients included gram-positive cocci (42.59% [OSSA, 13.33%; ORSA, 20.37%]), gram-negative bacilli (39.63% [P. aeruginosa, 9.26%; S. maltophilia, 1.11%; Acinetobacter species, 3.33%), and miscellaneous pathogens (17.78%).Conclusions.Our data demonstrated that patients with HAP, compared with those with VAP, had a similar frequency of infection with ORSA but less commonly had infections due to P. aeruginosa, Acinetobacter species, and S. maltophilia. However, the overall frequency of infection with these pathogens was sufficiently high to warrant the use of empirical therapy likely to be active against them. Our data supports using the currently recommended empirical therapy for both HAP and VAP.

Download Full-text

Bacteriology and Comorbidities in Patients Requiring Surgical Management of Empyema

The American Surgeon ◽

10.1177/000313481808400438 ◽

2018 ◽

Vol 84 (4) ◽

pp. 599-603

Author(s):

Aaron Pinnola ◽

Yen-Hong Kuo ◽

Jason D. Sciarretta ◽

Alexander Mcintyre ◽

Robert Messier ◽

...

Keyword(s):

Community Acquired Pneumonia ◽

Coagulase Negative Staphylococcus ◽

Drug Abusers ◽

Median Length ◽

Cancer History ◽

Gram Negative ◽

Hospital Acquired Pneumonia ◽

Hospital Acquired ◽

Intravenous Drug Abusers ◽

And Staphylococcus Aureus

Concern over the changing bacteriology of empyema has led to numerous attempts to characterize the most common locoregional bacterial isolates. The purpose of this study is to better characterize the bacteriology and demographics in patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia requiring surgery for empyema. All patients diagnosed with empyema preoperatively and had either a video-assisted thoracoscopic or open decortication surgery from January 2010 to September 2015 were reviewed. Forty-seven patients were identified with a mean age of 54.7 ± 16.8 years (X ± SD). Sixty per cent of patients had CAP. Anaerobes were the most common isolate at 21 per cent, followed by Streptococcus species and Staphylococcus aureus (50% Methicillin Resistant). Coagulase-negative Staphylococcus species were the next most frequent at 13 per cent. Hospital-acquired pneumonia patients had a higher incidence of S. aureus infections ( P = 0.047). Cancer history had higher rates of both fungal ( P = 0.004) and gram-negative infections ( P = 0.03). Older patients had increased incidence of gram-negative infections ( P = 0.05). The median length of stay for CAP patient who were intravenous drug abusers (n = 3) were 31 days (95% confidence interval (CI) [15, NA]), which was significantly longer than the others (median 12 days, 95% CI: [9, 18], P = 0.014). Streptococcus pneumoniae was not found in any of the isolates. Our data reveal that anaerobes and Staphylococcus species have replaced S. pneumoniae as the major regional pathogens in surgically treated empyema. In addition, anaerobic isolates were found in higher incidence in CAP than previously reported.

Download Full-text

A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

Clinical Infectious Diseases ◽

10.1093/cid/ciab032 ◽

2021 ◽

Author(s):

Richard G Wunderink ◽

Antoine Roquilly ◽

Martin Croce ◽

Daniel Rodriguez Gonzalez ◽

Satoshi Fujimi ◽

...

Keyword(s):

Clinical Response ◽

Bacterial Pneumonia ◽

Double Blind Study ◽

Phase 3 ◽

Gram Positive ◽

Double Blind ◽

Intention To Treat ◽

The Difference ◽

Hospital Acquired ◽

Noninferiority Margin

Abstract Background Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are associated with high mortality rates. We evaluated the efficacy and safety of tedizolid (administered as tedizolid phosphate) for treatment of gram-positive ventilated HABP/VABP. Methods In this randomized, noninferiority, double-blind, double-dummy, global phase 3 trial, patients were randomized 1:1 to receive intravenous tedizolid phosphate 200 mg once daily for 7 days or intravenous linezolid 600 mg every 12 hours for 10 days. Treatment was 14 days in patients with concurrent gram-positive bacteremia. The primary efficacy end points were day 28 all-cause mortality (ACM; noninferiority margin, 10%) and investigator-assessed clinical response at test of cure (TOC; noninferiority margin, 12.5%) in the intention-to-treat population. Results Overall, 726 patients were randomized (tedizolid, n = 366; linezolid, n = 360). Baseline characteristics, including incidence of methicillin-resistant Staphylococcus aureus (31.3% overall), were well balanced. Tedizolid was noninferior to linezolid for day 28 ACM rate: 28.1% and 26.4%, respectively (difference, –1.8%; 95% confidence interval [CI]: –8.2 to 4.7). Noninferiority of tedizolid was not demonstrated for investigator-assessed clinical cure at TOC (tedizolid, 56.3% vs linezolid, 63.9%; difference, –7.6%; 97.5% CI: –15.7 to 0.5). In post hoc analyses, no single factor accounted for the difference in clinical response between treatment groups. Drug-related adverse events occurred in 8.1% and 11.9% of patients who received tedizolid and linezolid, respectively. Conclusions Tedizolid was noninferior to linezolid for day 28 ACM in the treatment of gram-positive ventilated HABP/VABP. Noninferiority of tedizolid for investigator-assessed clinical response at TOC was not demonstrated. Both drugs were well tolerated. Clinical Trials Registration NCT02019420.

Download Full-text

1476. Impact of an Educational Campaign on Rates of Sputum Culture Acquisition as an Opportunity for Antibiotic De-escalation

Open Forum Infectious Diseases ◽

10.1093/ofid/ofaa439.1657 ◽

2020 ◽

Vol 7 (Supplement_1) ◽

pp. S739-S739

Author(s):

Jessica Snawerdt ◽

Derek N Bremmer ◽

Dustin R Carr ◽

Thomas L Walsh ◽

Tamara Trienski ◽

...

Keyword(s):

Length Of Stay ◽

Hospital Mortality ◽

Community Acquired Pneumonia ◽

Sputum Culture ◽

Post Intervention ◽

Significant Difference ◽

Educational Campaign ◽

The Difference ◽

Hospital Acquired ◽

Culture Acquisition

Abstract Background The 2019 community-acquired pneumonia (CAP) guidelines recommend obtaining a sputum culture in patients who are empirically treated for methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa to assist clinicians in optimizing antimicrobial therapy. A previous study at our institution found respiratory cultures were rarely obtained in patients with CAP. As a result of these findings, an educational campaign was implemented to promote the use of an induced sputum protocol. Methods This was a multicenter, retrospective cohort study that included patients who were ≥18 years of age, had a diagnosis of CAP, and received ≥48 hours of anti-pseudomonal antibiotics. Patients were excluded if mechanically ventilated within 48 hours of admission or diagnosed with hospital-acquired or ventilator-associated pneumonia. Patients were grouped into pre- and post-intervention time periods. The intervention involved education on obtaining respiratory cultures including technique on induced sputums and updates to CAP order sets. The primary outcome was the rate of sputum culture acquisition. Secondary outcomes included duration of anti-pseudomonal and anti-MRSA therapy, in-hospital mortality, and length of stay. Results A total of 143 patients met inclusion criteria, 72 in the pre-implementation group and 71 in the post-implementation group. Baseline characteristics were similar between the two groups. More patients in the post-implementation group had a sputum culture obtained but the difference was not statistically significant (38.9% vs 53.5%; p=0.08). Anti-pseudomonal therapy was continued for an average of 5.6 days pre-implementation and 5.2 days post-implementation (p=0.499). There was also not a significant difference in anti-MRSA duration between the two groups (3.4 days vs 3.2 days; p=0.606). In-hospital mortality and length of stay were similar between the two groups. Conclusion An educational campaign focusing on the acquisition of induced sputums led to an increase in rates of sputum cultures collected. However, this did not correlate with a decrease in duration of anti-MRSA or anti-pseudomonal therapy. Further interventions should be made to optimize de-escalation of broad spectrum antibiotics based on sputum culture results. Disclosures All Authors: No reported disclosures

Download Full-text

Clinical Presentation and Bacterial Etiology of Adult Community Acquired Pneumonia

Journal of Bangladesh College of Physicians and Surgeons ◽

10.3329/jbcps.v34i3.32343 ◽

2017 ◽

Vol 34 (3) ◽

pp. 128-134

Author(s):

Md Abdus Salam ◽

Md Robed Amin ◽

Quazi Tarikul Islam

Keyword(s):

Streptococcus Pneumoniae ◽

Blood Culture ◽

Mycoplasma Pneumoniae ◽

Chlamydia Pneumoniae ◽

Community Acquired Pneumonia ◽

Sputum Culture ◽

Gram Positive ◽

Gram Negative ◽

The Mean ◽

Gram Positive Cocci

Introduction: Pneumonia is a worldwide, serious threat to health and an enormous socio-economic burden for health care system. According to recent WHO data, each year 3-4 million patients die from pneumonia. The clinical presentations and bacterial agents responsible for community acquired pneumonia (CAP) varies according to geography and culture.Methods: A cross sectional observational study conducted among the 53 consecutive patients with a clinical diagnosis of CAP in admitted patient in the department of Medicine, DMCH, during January 2010 to December 2010. Hematological measurements (TC of WBC, Hb%, ESR, platelet count), blood culture, chest X-ray P/A view, sputum for Gram staining and culture sensitivity, sputum for AFB, blood urea and random blood sugar were done in all cases. ELISA for IgM antibody of Mycoplasma pneumoniae and Chlamydia pneumoniae were done in sputum culture negative cases.Results: The mean (±SD) age was 38.9±17.3 years and Male female ratio was 3:1. Fever, chest pain and productive cough were the most common clinical features. The mean (±SD) respiratory rate was 23.0±2.8 /minute . COPD and DM were found in 17.0% and 5.7% of patients respectively . Blood culture was found positive in only 1.9% of the study patients. Gram positive Cocci 62.26%, Gram negative Bacilli 9.43%, mixed Gram positive cocci and Gram negative bacilli 11.32% and Gram negative Cocco Bacilli 1.9% were observed and in 15.03 % cases, no bacteria could be seen. Sputum culture revealed 53.8% streptococcus pneumoniae, 26.9% Klebsiella pneumonia as predominant organism. Mycoplasma pneumoniae and Chlamydia pneumoniae were found in 7.4% and 3.7% respectively by serological test. For Streptococcus pneumoniae, sensitive antibiotics were Amoxyclav and Levofloxacin. For Gram negative bacilli and coccobacilli, more sensitive antibiotics were Meropenem, Ceftriaxone, and Clarithromycin. The best sensitive drug were found meropenem. The mean (±SD) duration of hospital stay was 5.0±1.7 days with ranging from 3 to 10 days.Conclusion: Region based bacteroiological diagnosis of Cap is important for selecting the best and sensitive drugs for complete cure.J Bangladesh Coll Phys Surg 2016; 34(3): 128-134

Download Full-text

Management of Health-Care Associated Pneumonia (HCAP)

Italian Journal of Medicine ◽

10.4081/itjm.2012.87 ◽

2013 ◽

pp. 87-90

Author(s):

Alessia Rosato ◽

Claudio Santini

Keyword(s):

Health Care ◽

Treatment Approach ◽

Multidrug Resistant ◽

Outpatient Setting ◽

Community Acquired Pneumonia ◽

Traditional Classification ◽

Hospital Acquired Pneumonia ◽

Health Care Associated Pneumonia ◽

Hospital Acquired

Introduction The traditional classification of Pneumonia as either community acquired (CAP) or hospital acquired (HAP) reflects deep differences in the etiology, pathogenesis, approach and prognosis between the two entities. Health-Care Associated Pneumonia (HCAP) develops in a heterogeneous group of patients receiving invasive medical care or surgical procedures in an outpatient setting. For epidemiology and outcomes, HCAP closely resembles HAP and possibly requires an analogous therapeutic regimen effective against multidrug-resistant pathogens. Materials and methods We reviewed the pertinent literature and the guidelines for the diagnosis and management of HCAP to analyze the evidence for the recommended approach. Results Growing evidence seems to confirm the differences in epidemiology and outcome between HCAP and CAP but fails to confirm any real advantage in pursuing an aggressive treatment for all HCAP and CAP patients. Discussion Further investigations are needed to establish the optimal treatment approach according to the different categories of patients and the different illness severities. Keywords Health Care Associated Pneumonia (HCAP); Community Acquired Pneumonia (CAP); Hospital Acquired Pneumonia (HAP); Multidrug-resistant (MDR) Pathogens

Download Full-text

Pulmonary Infections

Chest Imaging ◽

10.1093/med/9780199858064.003.0033 ◽

2019 ◽

pp. 187-189

Author(s):

Santiago Martínez-Jiménez

Keyword(s):

Antibiotic Therapy ◽

Treatment Failure ◽

Clinical Response ◽

Chest Radiography ◽

Community Acquired Pneumonia ◽

Clinical Perspective ◽

Immunosuppressed Patients ◽

Hospital Acquired Pneumonia ◽

Healthcare Associated ◽

Hospital Acquired

Pneumonia can be classified as: community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), healthcare-associated pneumonia (HCAP), and pneumonia in immunosuppressed patients. Although the above are similar pathologically, they are very different from a clinical perspective. Chest radiography is often performed to support the diagnosis and to determine the extent of involvement prior to the onset of therapy. Radiography should not be performed in the short term in patients who are improving clinically as it can lead to the misdiagnosis of treatment failure. Chest radiography in patients treated for pneumonia should only be obtained before 4-6 weeks after the onset of therapy if there is a failure of clinical response or if complications of pneumonia are clinically suspected. The majority of pneumonias will resolve after 6 weeks of appropriate antibiotic therapy.

Download Full-text

Factors influencing mortality in hospital-acquired pneumonia caused by Gram-negative bacteria in China

Journal of Infection and Public Health ◽

10.1016/j.jiph.2019.02.014 ◽

2019 ◽

Vol 12 (5) ◽

pp. 630-633 ◽

Cited By ~ 3

Author(s):

Ding-Yun Feng ◽

Yu-Qi Zhou ◽

Xiao-Ling Zou ◽

Mi Zhou ◽

Wen-Bin Wu ◽

...

Keyword(s):

Gram Negative Bacteria ◽

Gram Negative ◽

Factors Influencing ◽

Hospital Acquired Pneumonia ◽

Hospital Acquired

Download Full-text

Clinical characteristics of patients with pneumonia caused by Klebsiella pneumoniae in Taiwan and prevalence of antimicrobial-resistant and hypervirulent strains: a retrospective study

Antimicrobial Resistance and Infection Control ◽

10.1186/s13756-019-0660-x ◽

2020 ◽

Vol 9 (1) ◽

Cited By ~ 2

Author(s):

Chih-Han Juan ◽

Shih-Yu Fang ◽

Chia-Hsin Chou ◽

Tsung-Ying Tsai ◽

Yi-Tsung Lin

Keyword(s):

Retrospective Study ◽

Klebsiella Pneumoniae ◽

Clinical Characteristics ◽

Community Acquired Pneumonia ◽

Drug Resistant ◽

Hospital Acquired Pneumonia ◽

Resistant Strains ◽

Healthcare Associated ◽

Drug Resistant Strains ◽

Hospital Acquired

Abstract Background We aimed to compare the clinical characteristics of patients with community-acquired pneumonia (CAP), healthcare-associated pneumonia (HCAP), and hospital-acquired pneumonia (HAP) caused by Klebsiella pneumoniae and analyze the antimicrobial resistance and proportion of hypervirluent strains of the microbial isolates. Methods We conducted a retrospective study on patients with pneumonia caused by K. pneumoniae at the Taipei Veterans General Hospital in Taiwan between January 2014 and December 2016. To analyze the clinical characteristics of these patients, data was extracted from their medical records. K. pneumoniae strains were subjected to antimicrobial susceptibility testing, capsular genotyping and detection of the rmpA and rmpA2 genes to identify hypervirulent strains. Results We identified 276 patients with pneumonia caused by K. pneumoniae, of which 68 (24.6%), 74 (26.8%), and 134 (48.6%) presented with CAP, HCAP, and HAP, respectively. The 28-day mortality was highest in the HAP group (39.6%), followed by the HCAP (29.7%) and CAP (27.9%) groups. The HAP group also featured the highest proportion of multi-drug resistant strains (49.3%), followed by the HCAP (36.5%) and CAP groups (10.3%), while the CAP group had the highest proportion of hypervirulent strains (79.4%), followed by the HCAP (55.4%) and HAP groups (41.0%). Conclusion Pneumonia caused by K. pneumoniae was associated with a high mortality. Importantly, multi-drug resistant strains were also detected in patients with CAP. Hypervirulent strains were prevalent in all 3 groups of pneumonia patients, even in those with HAP.

Download Full-text

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00018-17 ◽

2017 ◽

Vol 61 (5) ◽

Cited By ~ 30

Author(s):

Michael A. Pfaller ◽

Michael D. Huband ◽

Paul R. Rhomberg ◽

Robert K. Flamm

Keyword(s):

Latin America ◽

North America ◽

Klebsiella Oxytoca ◽

Enterobacter Aerogenes ◽

Community Acquired Pneumonia ◽

Asia Pacific ◽

Gram Positive ◽

Gram Negative ◽

Content Type ◽

Viridans Group Streptococci

ABSTRACT Omadacycline is a broad-spectrum aminomethylcycline in late-stage clinical development for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia as an oral and an intravenous once-daily formulation. In this study, omadacycline and comparators were tested against 69,246 nonduplicate bacterial isolates collected prospectively during 2010 and 2011 from medical centers in Asia-Pacific (11,397 isolates), Europe (23,490 isolates), Latin America (8,038 isolates), and North America (26,321 isolates). Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A10 (2015) methods. A total of 99.9% of Staphylococcus aureus isolates were inhibited by ≤2 μg/ml of omadacycline (MIC50/90, 0.12/0.25 μg/ml), including 100.0% of methicillin-susceptible S. aureus isolates and 99.8% of methicillin-resistant S. aureus isolates. Omadacycline potencies were comparable for Streptococcus pneumoniae (MIC50/90, 0.06/0.06 μg/ml), viridans group streptococci (MIC50/90, 0.06/0.12 μg/ml), and beta-hemolytic streptococci (MIC50/90, 0.06/0.12 μg/ml) regardless of species and susceptibility to penicillin. Omadacycline was active against Enterobacteriaceae and was most active against Escherichia coli (MIC50/90, 0.5/2 μg/ml), Enterobacter aerogenes (MIC50/90, 2/4 μg/ml), Klebsiella oxytoca (MIC50/90, 1/4 μg/ml), and Citrobacter spp. (MIC50/90, 1/4 μg/ml). Omadacycline was active against Haemophilus influenzae (MIC50/90, 1/1 μg/ml) regardless of β-lactamase status and against Moraxella catarrhalis (MIC50/90, 0.12/0.25 μg/ml). The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be a concern.

Download Full-text